Articles on this Page
- 12/03/19--07:00: _It’s #GivingTuesday!
- 12/05/19--11:18: _Updated #ASH19 Myel...
- 12/06/19--15:11: _ASH 2019: The Debat...
- 12/08/19--06:07: _ASH 2019: Treating ...
- 12/08/19--20:36: _ASH 2019: Explorin...
- 12/09/19--07:22: _ASH 2019: Targeting...
- 12/09/19--07:34: _ASH 2019: The Bone ...
- 12/10/19--12:42: _ASH 2019: CAR T-ce...
- 12/10/19--13:00: _ASH 2019: Liquid B...
- 12/10/19--14:38: _ASH 2019: A Wealth ...
- 12/03/19--07:00: It’s #GivingTuesday!
- 12/09/19--07:22: ASH 2019: Targeting BCMA in Multiple Myeloma
- 12/09/19--07:34: ASH 2019: The Bone Marrow Microenvironment Moves to the Forefront
- 12/10/19--12:42: ASH 2019: CAR T-cell therapy in Lymphoma, Myeloma and Leukemia
- 12/10/19--14:38: ASH 2019: A Wealth of CAR T Development in Myeloma
Donate to Myeloma Research Today It's Giving Tuesday! This year, we are donating 100% of Giving Tuesday proceeds to three cutting-edge myeloma research projects from our Myeloma Crowd Research Initiative (MCRI). Each project was carefully selected by our team and we believe each will have a lasting impact on myeloma research. Thank you [...]
Myeloma Crowd provides the final pre #ASH19 listing of the most relevant myeloma abstracts. The listing is intended to let the participants with an interest in myeloma to find and attend the most important oral presentations. In addition, anyone following ASH by way of the internet can click on the abstracts to see what is [...]
Today at the American Society of Hematology 2019 conference in an MMRF session “Current Obstacles in Myeloma Management: Debating the Evidence, Dr. Saad Usmani and Dr. Rafael Fonseca faced off on the question “Should Smoldering Myeloma be Treated”? Answer: At this time there is not enough agreement among Myeloma specialists to answer [...]
What would practicing clinicians do in the case of patients who were relapsed or refractory to 3 or 4 different classes of drugs? Ravi Vij, MBBS, Washington University School of Medicine at St. Louis asked this key question to an audience of hundreds of hematologists at this Friday Satellite Symposium session. Peter M. Voorhees, MD, [...]
What is CRISPR and how will it impact me? According to one myeloma expert, the biggest pre-ASH “buzz” this year centered around abstract 49: “First-In-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO-1 TCR and CRISPR/CAS9 Gene Edited to Eliminate Endogenous TCR and PD-1b(NYCE T cells) in Advanced [...]
B-cell maturation agent (BCMA) is a very popular target for multiple myeloma therapies currently in development. Gareth Morgan, MD, FRCP, FRCPath, PhD of NYU Langone joins the Myeloma Crowd at ASH to review the BCMA-targeting therapies being reviewed at the meeting. There are three key immunotherapy approaches that all look highly effective for the [...]
The importance of the Bone Marrow Microenvironment as a key contributor to the disease process underlying Multiple Myeloma, starting from the early precursor stage of Monoclonal Gammopathy of Undetermined Significance (MGUS) to its active stage is increasingly being appreciated and studied. In a recent Plasma Cell Disorder Conference in Charlotte, NC, Dr. Ken Anderson said [...]
An educational symposium entitled “CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia- Clinical Updates and Innovations” was presented preceding the 61st American Society of Hematology (ASH) annual meeting and exposition. This symposium was extremely informative and focused on how CAR T-cell therapy, also known as Chimeric Antigen Receptor T-cell therapy, kills cancer. According to David [...]
At the 2019 American Society of Hematology (ASH) Meeting in Orlando, a group of investigators from several institutions including: Harvard Medical School, Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, Massachusetts General Hospital, Newton-Wellesley Hospital, the University of Rochester, and the University of Michigan presented a prize winning poster entitled Circulating Tumor DNA in [...]
There is so much CAR T development happening in myeloma, it's hard to keep track of it all. One of the sessions discussed relapsed and refractory myeloma strategies and almost all of the discussion centered around CAR T. Siddhartha Ganguly, MD of the University of Kansas shares the importance of CAR T trials and those [...]